Fresenius Kabi Oncology Limited

Sarbjot Singh Sokhi

Walter Cabri

Saswata Lahiri

Govind Singh

Maneesh Kumar Pandey

Raj Narayan Tiwari

Sonu Prasad Shukla

Heena Dua

Sachin Musmade

The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PGmay be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC. 

Process for the preparation of boronic acid esters

The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer. 

Process for the preparation of ribociclib and its salts

The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib. 

Process for purification of carfilzomib intermediate

The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %. 

Growing community of inventors

Haryana Gurugram, India

Sarbjot Singh Sokhi